12/2
08:41 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025 [Yahoo! Finance]
12/2
08:30 am
fulc
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
High
Report
Fulcrum Therapeutics to Host Investor Event to Review New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease on December 7, 2025
11/24
09:04 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $14.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Low
Report
Fulcrum Therapeutics (NASDAQ:FULC) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/24
07:19 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright.
11/7
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11/3
04:45 pm
fulc
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
Medium
Report
Fulcrum Therapeutics to Present New Clinical Data from the PIONEER trial of Pociredir in Sickle Cell Disease at the 67th American Society of Hematology Annual Meeting
10/30
11:02 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its price target raised by analysts at Royal Bank Of Canada from $5.00 to $7.00. They now have a "sector perform" rating on the stock.
10/30
08:13 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
10/29
07:00 am
fulc
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
Medium
Report
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2025
10/22
08:54 am
fulc
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
Medium
Report
Fulcrum Therapeutics to Host Third Quarter 2025 Financial Results Conference Call and Webcast on Wednesday, October 29, 2025, at 8:00 a.m. ET
10/21
06:01 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $20.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) was given a new $20.00 price target on by analysts at Leerink Partners. They now have an "outperform" rating on the stock.
10/20
08:08 am
fulc
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Medium
Report
Fulcrum Therapeutics (NASDAQ:FULC) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
10/14
07:20 am
fulc
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 [Yahoo! Finance]
Low
Report
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025 [Yahoo! Finance]
10/14
07:00 am
fulc
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
Low
Report
Fulcrum Therapeutics to Present Preclinical Data for EED Inhibitor FTX-6274 at European Society for Medical Oncology (ESMO) Congress 2025
10/10
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
9/12
04:30 pm
fulc
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)